PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
8935.00 - 9125.00
6347.00 - 10045.00
380.0K / 335.9K (Avg.)
23.15 | 391.09
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-3.99%
Negative revenue growth while Medical - Pharmaceuticals median is 0.18%. Seth Klarman would investigate if the company is losing market share or facing a declining industry.
-3.25%
Negative gross profit growth while Medical - Pharmaceuticals median is 0.95%. Seth Klarman would suspect poor product pricing or inefficient production.
-19.17%
Negative EBIT growth while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would check if external or internal factors caused the decline.
-27.13%
Negative operating income growth while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would check if structural or cyclical issues are at play.
-25.66%
Negative net income growth while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate factors dragging net income down.
-25.65%
Negative EPS growth while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would explore whether share dilution or profit declines are to blame.
-25.65%
Negative diluted EPS growth while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would look for the cause: weakened profitability or heavier share issuance.
-0.00%
Share reduction while Medical - Pharmaceuticals median is 0.08%. Seth Klarman would see a relative advantage if others are diluting.
-0.00%
Diluted share reduction while Medical - Pharmaceuticals median is 0.02%. Seth Klarman would see an advantage if others are still diluting.
No Data
No Data available this quarter, please select a different quarter.
5.51%
OCF growth of 5.51% while Medical - Pharmaceuticals is zero. Walter Schloss might see a modest positive difference, which can compound over time.
5.51%
FCF growth exceeding 1.5x Medical - Pharmaceuticals median of 1.60%. Joel Greenblatt would see if high profitability or prudent capex drives outperformance.
27.44%
10Y revenue/share CAGR near Medical - Pharmaceuticals median of 26.42%. Charlie Munger might expect stable industry trends guiding long-term growth.
49.80%
5Y revenue/share growth exceeding 1.5x Medical - Pharmaceuticals median of 14.35%. Joel Greenblatt would see if the company’s moat drives rapid mid-term expansion.
23.09%
3Y revenue/share growth exceeding 1.5x Medical - Pharmaceuticals median of 5.11%. Joel Greenblatt might see a short-term competitive advantage at play.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
13.42%
Net income/share CAGR exceeding 1.5x Medical - Pharmaceuticals median of 8.41% over a decade. Joel Greenblatt might see a standout compounder of earnings.
53.29%
5Y net income/share CAGR > 1.5x Medical - Pharmaceuticals median of 4.47%. Joel Greenblatt might see superior mid-term capital allocation or product strength.
29.45%
3Y net income/share CAGR > 1.5x Medical - Pharmaceuticals median of 7.83%. Joel Greenblatt might see a recent surge from market share gains or cost synergy.
143.96%
Equity/share CAGR of 143.96% while Medical - Pharmaceuticals median is zero. Walter Schloss might see a modest advantage in net worth accumulation that could matter long term.
100.32%
5Y equity/share CAGR > 1.5x Medical - Pharmaceuticals median of 13.66%. Joel Greenblatt sees a possible ROE advantage or fewer share issuances boosting book value.
49.44%
3Y equity/share CAGR > 1.5x Medical - Pharmaceuticals median of 12.97%. Joel Greenblatt sees strong short-term returns on equity fueling net worth growth.
112.50%
Dividend/share CAGR of 112.50% while Medical - Pharmaceuticals is zero. Walter Schloss sees a minor improvement that could compound if the firm maintains consistent raises.
88.89%
5Y dividend/share CAGR of 88.89% while Medical - Pharmaceuticals is zero. Walter Schloss sees at least some improvement that could compound over time.
70.00%
3Y dividend/share CAGR of 70.00% while Medical - Pharmaceuticals is zero. Walter Schloss sees a slight advantage if the firm is at least inching up payouts.
29.48%
AR growth of 29.48% while Medical - Pharmaceuticals median is zero. Walter Schloss checks if the difference points to new credit strategy or stronger sales push.
10.13%
Inventory growth of 10.13% while Medical - Pharmaceuticals median is zero. Walter Schloss checks if we’re preparing for a sales push or risking overstock.
1.50%
Asset growth of 1.50% while Medical - Pharmaceuticals median is zero. Walter Schloss sees a slight advantage if expansions yield good returns on capital.
2.47%
BV/share growth of 2.47% while Medical - Pharmaceuticals is zero. Walter Schloss sees a slight lead that can expand if sustained over time.
-8.57%
Debt is shrinking while Medical - Pharmaceuticals median is rising. Seth Klarman might see an advantage if growth remains possible.
No Data
No Data available this quarter, please select a different quarter.
3.12%
SG&A growth far above Medical - Pharmaceuticals median. Jim Chanos sees potential red flags in cost management or diminishing returns on spending.